Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

TPEX:6712 Revenue

Ever Supreme Bio Technology had revenue of 321.49M TWD in the quarter ending September 30, 2026, with 22.15% growth. This brings the company's total for the last twelve months to 1.14B, up 13.26% year-over-year. In the year 2025, Ever Supreme Bio Technology had annual revenue of 1.02B with 8.96% growth. That makes Ever Supreme Bio Technology the 30,468th largest company in the world by revenue and 1,509th in Taiwan.

• Revenue (ttm): 1.14B
• Revenue Growth: +13.26%
• P/S Ratio: 13.08
• Revenue / Employee: n/a
• Employees: 94
• Market Cap: 14.91B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Cell Preparations 773.25M 76.0%
• Other 244.25M 24.0%

Fiscal year ended Dec 31, 2025 See the full TPEX:6712 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.02B	83.69M	8.96%
Dec 31, 2024	933.81M	175.42M	23.13%
Dec 31, 2023	758.39M	130.88M	20.86%
Dec 31, 2022	627.51M	188.67M	42.99%
Dec 31, 2021	438.84M	368.24M	521.61%

Data Source: S&P Global Market Intelligence Last updated: Nov 9, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 13, 2026

Data Sources Report a data error